{
    "root": "2fb1eb1d-4c38-a095-e063-6294a90a3673",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "CELECOXIB",
    "value": "20250306",
    "ingredients": [
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "POVIDONE",
            "code": "FZ989GH94E",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11061"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16189"
        },
        {
            "name": "GELATIN",
            "code": "2G86QN327L",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5291"
        },
        {
            "name": "CELECOXIB",
            "code": "JCX84Q7J1L",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_41423"
        }
    ],
    "indications": {
        "text": "celecoxib non-steroidal anti-inflammatory indicated : osteoarthritis ( oa ) ( 1.1 ) rheumatoid arthritis ( rheumatoid arthritis ) ( 1.2 ) juvenile rheumatoid arthritis ( jra ) patients 2 years older ( 1.3 ) ankylosing spondylitis ( ) ( 1.4 ) acute pain ( ap ) ( 1.5 ) primary dysmenorrhea ( pd ) ( 1.6 )",
        "doid_entities": [
            {
                "text": "osteoarthritis (DOID:8398)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8398"
            },
            {
                "text": "rheumatoid arthritis (DOID:7148)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_7148"
            },
            {
                "text": "arthritis (DOID:848)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_848"
            },
            {
                "text": "juvenile rheumatoid arthritis (DOID:676)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_676"
            },
            {
                "text": "ankylosing spondylitis (DOID:7147)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_7147"
            },
            {
                "text": "spondylitis (DOID:6590)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6590"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "lowest effective shortest duration consistent individual patient treatment goals ( 2.1 ) oa : 200 mg daily 100 mg twice daily ( 2.2 , 14.1 ) rheumatoid arthritis : 100 mg 200 mg twice daily ( 2.3 , 14.2 ) jra : 50 mg twice daily patients 10 kg 25 kg . 100 mg twice daily patients 25 kg ( 2.4 , 14.3 ) : 200 mg daily single dose 100 mg twice daily . effect observed 6 weeks , trial 400 mg ( single divided doses ) may benefit ( 2.5 , 14.4 ) ap pd : 400 mg initially , followed 200 mg dose needed first day . subsequent days , 200 mg twice daily needed ( 2.6 , 14.5 ) hepatic impairment : reduce daily dose 50 % patients moderate hepatic impairment ( child-pugh class b ) . ( 2.7 , 8.6 , 12.3 ) poor metabolizers cyp2c9 substrates : consider dose reduction 50 % ( alternative management jra ) patients known suspected cyp2c9 poor metabolizers , ( 2.7 , 8.8 , 12.3 ) .",
        "doid_entities": [
            {
                "text": "rheumatoid arthritis (DOID:7148)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_7148"
            },
            {
                "text": "arthritis (DOID:848)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_848"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "celecoxib capsules available following strengths configurations : product name celecoxib capsules 200 mg white white colored granules filled size 1 hard gelatin white capsule axially printed 'cipla ' cap & '421 ' '200 mg ' body gold ink . ndc : 70518-2233-00 ndc : 70518-2233-01 ndc : 70518-2233-02 packaging : 30 1 bottle plastic packaging : 100 1 box packaging : 1 1 pouch storage : store 25\u00b0c ( 77\u00b0f ) excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) [ usp controlled room temperature ] . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "known hypersensitivity celecoxib , components product sulfonamides ( 4 ) history asthma , urticaria , allergic-type taking aspirin nsaids ( 4 ) setting cabg surgery ( 4 )",
    "indications_original": "Celecoxib is a non-steroidal anti-inflammatory drug indicated for: Osteoarthritis (OA) ( 1.1 ) Rheumatoid Arthritis (RA) ( 1.2 ) Juvenile Rheumatoid Arthritis (JRA) in      patients 2 years and older ( 1.3 ) Ankylosing Spondylitis (AS) ( 1.4 ) Acute Pain (AP) ( 1.5 ) Primary Dysmenorrhea (PD) ( 1.6 )",
    "contraindications_original": "Use the lowest effective dosage for shortest duration consistent with individual patient treatment goals ( 2.1 ) OA: 200 mg once daily or 100 mg twice daily ( 2.2 , 14.1 ) RA: 100 mg to 200 mg twice daily ( 2.3 , 14.2 ) JRA: 50 mg twice daily in patients 10 kg to 25 kg. 100 mg twice daily in patients more than 25 kg ( 2.4 , 14.3 ) AS: 200 mg once daily single dose or 100 mg twice daily. If no effect is observed after 6 weeks, a trial of 400 mg (single or divided doses) may be of benefit ( 2.5 , 14.4 ) AP and PD: 400 mg initially, followed by 200 mg dose if needed on first day. On subsequent days, 200 mg twice daily as needed ( 2.6 , 14.5 ) Hepatic Impairment: Reduce daily dose by 50% in patients with moderate hepatic impairment (Child-Pugh Class B). ( 2.7 , 8.6 , 12.3 ) Poor Metabolizers of CYP2C9 Substrates: Consider a dose reduction by 50% (or alternative management for JRA) in patients who are known or suspected to be CYP2C9 poor metabolizers, ( 2.7 , 8.8 , 12.3 ).",
    "warningsAndPrecautions_original": "Celecoxib Capsules are available in the following strengths and configurations:\n                  Product Name\n  \n                     \nCelecoxib Capsules 200 mg\n  \n                     \nWhite to off white colored granules filled in size 1 hard gelatin white capsule axially printed with 'Cipla' on cap & '421' over '200 mg' on body in gold ink.\n \n                  \n                  NDC: 70518-2233-00\n                  NDC: 70518-2233-01\n                  NDC: 70518-2233-02\n                  PACKAGING: 30 in 1 BOTTLE PLASTIC \n                  PACKAGING: 100 in 1 BOX \n                  PACKAGING: 1 in 1 POUCH\n                  \n                  \n                     \n                        Storage:\n                     \n                  \n                  Store at 25\u00b0C (77\u00b0F) excursions permitted to 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F) [see USP Controlled Room Temperature].\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Known hypersensitivity to celecoxib, or any components of the drug product or sulfonamides ( 4 ) History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs ( 4 ) In the setting of CABG surgery ( 4 )",
    "drug": [
        {
            "name": "CELECOXIB",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_41423"
        }
    ]
}